ADTX - Aditx Therapeutics Inc Stock Price, Fair Value and News

2.19USD-0.11 (-4.78%)Delayed as of 06 May 2024, 12:46 pm ET

Market Summary

USD2.19-0.11

Delayedas of 06 May 2024, 12:46 pm

-4.78%

ADTX Stock Price

View Fullscreen

ADTX RSI Chart

ADTX Valuation

Market Cap

3.8M

Price/Earnings (Trailing)

-0.12

Price/Sales (Trailing)

4.94

EV/EBITDA

-0.13

Price/Free Cashflow

-0.21

ADTX Price/Sales (Trailing)

ADTX Profitability

EBT Margin

-4178.42%

Return on Equity

-201.67%

Return on Assets

-72.64%

Free Cashflow Yield

-485.41%

ADTX Fundamentals

ADTX Revenue

Revenue (TTM)

775.2K

Rev. Growth (Yr)

-71.39%

Rev. Growth (Qtr)

559.95%

ADTX Earnings

Earnings (TTM)

-32.4M

Earnings Growth (Yr)

-34.03%

Earnings Growth (Qtr)

-12.54%

Breaking Down ADTX Revenue

52 Week Range

2.37

(Low)(High)

Last 7 days

-3.3%

Last 30 days

-25.2%

Last 90 days

-38.1%

Trailing 12 Months

-91.2%

How does ADTX drawdown profile look like?

ADTX Financial Health

Current Ratio

0.27

ADTX Investor Care

Shares Dilution (1Y)

1278.28%

Diluted EPS (TTM)

-108.87

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	1.8M	1.8M	1.5M	775.2K
2022	693.1K	1.1M	1.4M	1.8M
2021	0	0	0	335.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Aditx Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 07, 2023	bnp paribas securities corp	sold	-691,140	33.2279	-20,800	-
Jul 19, 2022	albanna amro a.	bought	20,000	20,000	1.00	chief executive officer
Jun 04, 2021	albanna amro a.	acquired	-	-	75,000	chief executive officer
Jun 04, 2021	albanna rowena	acquired	-	-	75,000	chief operating officer
Jun 04, 2021	pankovcin corinne	acquired	-	-	55,000	chief financial officer
Jun 01, 2021	albanna amro a.	bought	9,974	2.93353	3,400	chief executive officer
Jun 01, 2021	runge jeffrey w.	bought	29,343	2.93437	10,000	-
Jun 01, 2021	albanna rowena	bought	9,974	2.93353	3,400	chief operating officer
Jun 01, 2021	shabahang shahrokh	bought	1,435	2.93	490	chief innovation officer
May 27, 2021	shabahang shahrokh	bought	499	2.7	185	chief innovation officer

Which funds bought or sold ADTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 19, 2024	Cutler Group LLC / CA	sold off	-100	-	-	-%
Apr 12, 2024	Game Plan Financial Advisors, LLC	sold off	-100	-7.00	-	-%
Feb 14, 2024	Schonfeld Strategic Advisors LLC	sold off	-100	-423,411	-	-%
Feb 13, 2024	Qube Research & Technologies Ltd	reduced	-41.67	-10,347	4,641	-%
Feb 13, 2024	MORGAN STANLEY	unchanged	-	-217	245	-%
Feb 13, 2024	ARMISTICE CAPITAL, LLC	sold off	-100	-349,720	-	-%
Feb 13, 2024	Tower Research Capital LLC (TRC)	reduced	-48.09	-17,028	6,478	-%
Feb 13, 2024	NATIXIS	unchanged	-	-1,708	1,575	-%
Feb 12, 2024	OSAIC HOLDINGS, INC.	unchanged	-	-64.00	72.00	-%

Are Funds Buying or Selling ADTX?

Are funds buying ADTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ADTX

No. of Funds

Unveiling Aditx Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	cvi investments, inc.	0.5%	2,066	SC 13G/A
Feb 06, 2024	intracoastal capital, llc	1.5%	6,918	SC 13G/A
Jan 02, 2024	sabby management, llc	4.99%	22,048	SC 13G/A
Feb 14, 2023	cvi investments, inc.	9.9%	476,762	SC 13G/A
Feb 08, 2023	intracoastal capital, llc	5.8%	262,500	SC 13G/A
Jan 04, 2023	sabby management, llc	9.99%	415,697	SC 13G
Sep 27, 2022	cvi investments, inc.	9.9%	242,341	SC 13G
Sep 26, 2022	intracoastal capital, llc	9.99%	4	SC 13G
Jan 04, 2022	sabby management, llc	4.99%	2,170,897	SC 13G/A
Sep 03, 2021	sabby management, llc	9.99%	1,935,221	SC 13G

Recent SEC filings of Aditx Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 03, 2024	8-K	Current Report
May 03, 2024	8-K/A	Current Report
Apr 16, 2024	10-K	Annual Report
Apr 12, 2024	8-K	Current Report
Apr 04, 2024	8-K	Current Report
Apr 01, 2024	NT 10-K	NT 10-K
Mar 11, 2024	8-K	Current Report
Mar 04, 2024	425	Prospectus Filed
Mar 04, 2024	8-K	Current Report
Mar 01, 2024	8-K	Current Report

Peers (Alternatives to Aditx Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.9B	6.8B	23.52%	-6.94%	-8.03	7	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	0.99%	-25.83%	-58.02	9.62	75.20%	68.82%
BMRN	15.7B	2.5B	-4.94%	-13.58%	76.24	6.34	13.74%	186.89%
INCY	12.1B	3.8B	-2.80%	-18.78%	16.19	3.2	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-16.72%	-43.78%	-10.83	14.43	425.83%	18.94%
BBIO	5.2B	107.9M	-4.79%	106.15%	-9.53	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	1.74%	5.10%	-14.81	13.1	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.74%	-39.00%	-10.2	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.55%	-20.97%	-45.84	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-4.91%	-11.58%	24.31	4.36	85.90%	-14.05%
NVAX	687.2M	983.7M	8.15%	-35.14%	-1.26	0.7	-50.36%	17.16%
CRBP	408.0M	881.7K	0.99%	345.87%	-9.15	466.16	-77.61%	-5.33%
INO	282.8M	4.9M	-1.94%	21.49%	-2.09	58.11	-54.97%	51.71%
IBIO	6.9M	2.1M	-32.65%	86.79%	-0.25	2.14	-13.45%	66.37%

Aditx Therapeutics Inc News

Latest updates

Aditx Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	559.9%	291,606	44,186	220,978	218,415	1,019,407	323,125	214,715	210,279	-
Gross Profit	-1264.7%	-204,570	17,564	35,240	40,106	15,430	89,441	39,857	22,208	-
Operating Expenses	-4.5%	7,746,314	8,112,773	4,269,677	5,822,001	8,215,476	5,481,605	5,810,814	6,139,139	24,020,799
S&GA Expenses	-283.6%	-13,161,843	7,169,863	113,759	4,368,843	5,130,329	3,919,618	833,942	4,624,158	21,831,827
R&D Expenses	378.8%	4,303,239	898,724	484,835	1,387,541	3,081,242	1,570,540	1,187,920	1,428,382	1,702,370
EBITDA Margin	-102.7%	-38.27	-18.88	-14.70	-14.86	-14.97	-30.58	-43.10	-65.84	-137
Interest Expenses	-	1,535,688	-	-	-	12,737	669,470	-	-	-
Earnings Before Taxes	-12.6%	-10,977,821	-9,745,902	-5,682,018	-5,984,706	-8,183,166	-7,557,563	-5,850,006	-6,059,141	-24,052,532
EBT Margin	-112.2%	-41.78	-19.69	-15.38	-15.53	-15.64	-30.88	-43.49	-66.44	-138
Net Income	-12.5%	-10,968,213	-9,745,902	-5,682,018	-5,984,706	-8,183,166	-7,557,563	-5,850,006	-6,059,141	-24,052,532
Net Income Margin	-112.1%	-41.77	-19.69	-15.38	-15.53	-15.64	-30.88	-43.49	-66.44	-138
Free Cashflow	-Infinity%	-3,309,261	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Assets	441.9%	44,578	8,226	7,294	7,634	10,735	19,180	10,740	11,792	16,664	19,587	15,905	18,017	13,097	15,368	-	-
Current Assets	101.7%	6,913	3,428	2,148	1,943	4,744	12,625	3,638	4,441	9,417	12,386	9,927	14,809	11,033	14,278	75.00	4.00
Cash Equivalents	-94.1%	97.00	1,651	1.00	303	2,769	9,245	804	2,115	7,872	5,469	8,610	14,045	10,501	13,716	50.00	4.00
Inventory	-13.1%	746	858	1,018	-	950	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-5.3%	1,898	2,004	-	-	2,319	-	-	-	-	-	-	-	-	-	-	-
Liabilities	129.2%	28,532	12,447	11,163	7,566	5,529	6,485	9,379	7,069	6,483	6,614	9,941	6,647	2,085	1,621	4,330	2,976
Current Liabilities	130.3%	25,890	11,243	9,744	5,910	3,644	4,373	7,041	4,515	3,607	3,601	5,228	3,405	1,227	756	4,330	2,976
Shareholder's Equity	-	16,056	-	-	68.00	5,206	12,694	1,361	4,723	10,181	12,972	5,964	11,370	11,011	13,747	-	-
Retained Earnings	-9.5%	-127,741	-116,620	-106,707	-101,025	-95,040	-86,828	-79,261	-73,411	-67,352	-43,300	-33,437	-27,258	-20,879	-16,198	-13,453	-11,729
Additional Paid-In Capital	27.9%	143,998	112,600	103,033	101,290	100,448	99,720	80,769	78,292	77,735	56,450	39,588	38,816	32,079	30,135	9,939	9,063
Shares Outstanding	548.9%	1,319	203	169	121	46.00	36.00	23.00	22.00	10.00	9.00	7.00	7.00	6.00	-	-	-
Float	-	-	-	3,008	-	-	-	7,923	-	-	-	32,725	-	-	-	20,080	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Cashflow From Operations	58.8%	-3,309	-8,033	-3,281	-3,951	-6,719	-7,818	-2,654	-5,199	-8,691	-4,525	-5,007	-4,053	-3,146	-3,669	-154	-250	-	-	-
Share Based Compensation	384.0%	745	154	163	339	614	632	1,284	601	1,504	899	772	1,465	1,625	874	160	529	-	-	-
Cashflow From Investing	100.0%	-	-9.36	-2*	-5.05	180	87.00	-135	-373	-8,482	-7,041	-294	-486	-	-	-	-	-	-	-
Cashflow From Financing	-81.7%	1,755	9,599	3,075	1,491	64.00	16,172	1,479	-184	19,576	8,427	-133	8,084	-58.48	17,495	158	293	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ADTX Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
REVENUE
Sales	$ 645,176	$ 933,715
Cost of goods sold	756,836	766,779
Gross profit (loss)	(111,660)	166,936
OPERATING EXPENSES
General and administrative expenses $1,133,077, and $1,516,805 in stock-based compensation, respectively	18,607,142	15,985,552
Research and development, includes $262,154, and $591,518 in stock-based compensation, respectively	7,074,339	7,268,084
Sales and marketing $6,787, and $1,023,045 in stock-based compensation, respectively	269,284	1,849,460
Impairment on notes receivable		543,938
Total operating expenses	25,950,765	25,647,034
NET LOSS FROM OPERATIONS	(26,062,425)	(25,480,098)
OTHER EXPENSE
Interest expense	(4,195,127)	(753,038)
Interest income	10,166	57,348
Other income		58,960
Amortization of debt discount	(2,194,773)	(1,533,048)
Gain on note exchange agreement	51,712
Total other expense	(6,328,022)	(2,169,778)
Net loss before income taxes	(32,390,447)	(27,649,876)
Income tax provision
NET LOSS	(32,390,447)	(27,649,876)
NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST	(9,608)
NET LOSS ATTRIBUTABLE TO ADITXT, INC. & SUBSIDIARIES	(32,380,839)	(27,649,876)
Deemed Dividend	(319,871)	(37,667)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ (32,700,710)	$ (27,687,553)
Net loss per share - basic and diluted (in Dollars per share)	$ (108.15)	$ (597.12)
Weighted average number of shares outstanding during the period - Basic (in Shares)	302,356	46,369

ADTX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash	$ 97,102	$ 2,768,640
Inventory	745,502	950,093
Prepaid expenses	217,390	496,869
Subscription receivable	5,444,628
TOTAL CURRENT ASSETS	6,912,948	4,743,563
Fixed assets, net	1,898,243	2,318,863
Intangible assets, net	9,444	107,000
Deposits	106,410	355,366
Right of use asset - long term	2,200,299	3,160,457
Deferred issuance costs		50,000
Investment in Evofem	22,277,211
Deposit on acquisition	11,173,772
TOTAL ASSETS	44,578,327	10,735,249
CURRENT LIABILITIES:
Accounts payable and accrued expenses	8,554,959	1,958,502
Notes payable, net of discount	15,653,477
Financing on fixed assets	147,823	409,983
Deferred rent	158,612	188,581
Lease liability - current	999,943	1,086,658
TOTAL CURRENT LIABILITIES	25,889,814	3,643,724
Settlement liability	1,600,000
Lease liability - long term	1,041,744	1,885,218
TOTAL LIABILITIES	28,531,558	5,528,942
Preferred stock, value
Common stock, $0.001 par value, 100,000,000 shares authorized, 1,318,969 and 107,698 shares issued and 1,318,918 and 107,647 shares outstanding, respectively	1,319	108
Treasury stock, 51 and 51 shares, respectively	(201,605)	(201,605)
Additional paid-in capital	143,997,710	100,448,166
Accumulated deficit	(127,741,072)	(95,040,362)
TOTAL ADITXT, INC. STOCKHOLDERS’ EQUITY (DEFICIT)	16,056,377	5,206,307
NON-CONTROLLING INTEREST	(9,608)
TOTAL STOCKHOLDERS’ EQUITY	16,046,769	5,206,307
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)	44,578,327	10,735,249
Unbilled
CURRENT ASSETS:
Accounts receivable, net	408,326	527,961
Series A-1 Convertible Preferred Stock
CURRENT LIABILITIES:
Preferred stock, value	22
Series B Preferred Stock
CURRENT LIABILITIES:
Preferred stock, value
Series B-2 Convertible Preferred Stock
CURRENT LIABILITIES:
Preferred stock, value	3
Series C Preferred Stock
CURRENT LIABILITIES:
Preferred stock, value
Related Party
CURRENT LIABILITIES:
Notes payable - related party	$ 375,000

About Aditx Therapeutics Inc

Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. It is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

CEO	Mr. Amro A. Albanna
WEBSITE	aditxt.com
INDUSTRY	Biotechnology
EMPLOYEES	61

Aditx Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Aditx Therapeutics Inc? What does ADTX stand for in stocks?

ADTX is the stock ticker symbol of Aditx Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aditx Therapeutics Inc (ADTX)?

As of Fri May 03 2024, market cap of Aditx Therapeutics Inc is 3.83 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ADTX stock?

You can check ADTX's fair value in chart for subscribers.

What is the fair value of ADTX stock?

You can check ADTX's fair value in chart for subscribers. The fair value of Aditx Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aditx Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ADTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aditx Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ADTX is over valued or under valued. Whether Aditx Therapeutics Inc is cheap or expensive depends on the assumptions which impact Aditx Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ADTX.

What is Aditx Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 03 2024, ADTX's PE ratio (Price to Earnings) is -0.12 and Price to Sales (PS) ratio is 4.94. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ADTX PE ratio will change depending on the future growth rate expectations of investors.